Galecto Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Galecto Inc
Access all reports
Galecto Inc. is a clinical-stage biotechnology company primarily focused on the development of small molecule therapeutics aimed at critical aspects of cancer and fibrotic diseases. Their research and development efforts are centered around the inhibition of galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins that play a pivotal role in the progression of these conditions. Galecto's portfolio includes GB0139, designed for treating Idiopathic Pulmonary Fibrosis (IPF), a serious progressive fibrotic lung disease; GB1211, a selective oral small molecule inhibitor of galectin-3 for various oncology indications and liver cirrhosis; and GB2064, targeting LOXL2 for the treatment of myelofibrosis. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GLTO
Country
🇺🇸 United States